ATLANTA--(BUSINESS WIRE)--March 13, 2006--
Amgen´s Phase 3 RED-HF(TM) Trial Will Evaluate the Clinical Effect
of Treating Anemia in Patients with Symptomatic Heart Failure
Amgen (Nasdaq:AMGN), the world´s largest biotechnology company,
announced results from a Phase 2 study that showed that treating
anemia with Aranesp(R) (darbepoetin alfa) in patients with symptomatic
heart failure was well-tolerated, effectively raised hemoglobin and
improved patients´ symptoms as measured by the Kansas City
Cardiomyopathy Questionnaire (KCCQ). The results were presented today
at the 2006 American College of Cardiology (ACC) Scientific Session.
"There is increasing evidence of a link between anemia and heart
failure, and of the potential that treating anemia in heart failure
patients may be beneficial over time," said Dirk J. van Veldhuisen,
M.D., Ph.D., FESC, FACC, Department of Cardiology/Thoracic Surgery,
University Medical Center, Groningen, Netherlands. "These data are
encouraging and support the need for a large-scale, definitive trial
to determine the effect of treating anemia in heart failure patients."
Based on the evaluation of the results of the Phase 2 program and
observational studies, Amgen has initiated the Phase 3 RED-HF(TM)
(Reduction of Events with Darbepoetin alfa in Heart Failure) Trial, a
randomized, double-blind, placebo-controlled, multicenter,
multinational trial that will evaluate the effect of treatment of
anemia with Aranesp on morbidity and mortality in patients with
symptomatic heart failure.
"Despite medical advances, heart failure and its complications are
a leading cause of death and hospitalization worldwide, and there
remains a significant unmet medical need for effective treatments for
these patients," said Willard Dere, M.D., senior vice president for
Global Development and chief medical officer at Amgen. "Amgen is
committed to investigating Aranesp´s potential to help heart failure
patients who also suffer from anemia through the RED-HF Trial."
About the Phase 2 Study
This 26-week study enrolled 165 patients with symptomatic heart
failure (New York Heart Association (NYHA) II-IV; HF duration greater
than or equal to 3 months), left ventricular ejection fraction (LVEF)
less than or equal to 40 percent and hemoglobin (Hb) levels of 9.0 to
12.5 g/dL. Patients were randomized to receive Aranesp subcutaneously
every two weeks at starting doses of 0.75 mcg/kg (n=56) or 50 mcg
(fixed dose; n=54) or placebo (n=55) to achieve and maintain a target
Hb of 14.0 +/- 1.0 g/dL. The primary endpoint was the rate of Hb rise
per week during the titration period. Other endpoints included change
from baseline to month six in six-minute walk distance, Patient´s
Global Assessment (PGA), Minnesota Living With Heart Failure
Questionnaire (MLHFQ), KCCQ and safety.
Investigators concluded that in patients with symptomatic heart
failure and anemia, treatment with Aranesp effectively raised Hb
levels, significantly improved KCCQ total symptom score (Aranesp 8.2
vs. placebo 1.5; p = 0.027) and had a similar adverse event profile as
previously seen in clinical trials with Aranesp. Statistically
nonsignificant improvements in PGA (Aranesp 65 percent vs. placebo 49
percent; p = 0.057), MLHFQ total score (Aranesp -10.1 vs. placebo
-7.4; p = 0.413) and 6-minute walk distance (Aranesp 34.2 m vs.
placebo 11.4 m; p = 0.074) were observed. Fixed dosing was as
effective as weight-based dosing in raising Hb levels (difference:
0.05 g/dL/wk; 95 percent CI 0.01, 0.09), and no change was observed in
NYHA class (Aranesp -0.30 vs. placebo -0.23; p = 0.473). The number of
adverse events was similar across treatment groups.
Amgen Cardiovascular Clinical Trials Program
Amgen has initiated an extensive clinical trials program to study
the effect of treating anemia or chronic kidney disease (CKD)
complications on cardiovascular outcomes in different patient
populations. In addition to the RED-HF Trial, Amgen initiated TREAT
(Trial to Reduce Cardiovascular Events with Aranesp Therapy), an
ongoing trial in diabetic patients with chronic kidney disease and
anemia not requiring dialysis and will initiate a trial that will
study the effect of treating the CKD complication, secondary
hyperparathyroidism, with Sensipar(R)/Mimpara(R) (cinacalcet HCl) in
end stage renal disease (ESRD) patients on dialysis on cardiovascular
Anemia and Heart Failure
Heart failure and its complications are a leading cause of death
and hospitalization worldwide, affecting over 23 million people
worldwide and five million people in the U.S. Heart failure alone is
the leading cause of hospitalization for people over the age of 65
years and causes almost one million hospitalizations every year.
Approximately 20 to 30 percent of people diagnosed with heart failure
also suffer from anemia, resulting in increased risk of morbidity and
mortality versus patients who suffer from heart failure without
anemia. Despite current, approved therapies to treat heart failure, a
significant unmet medical need to treat the disease and its
complications still exists.
About Aranesp(R) (darbepoetin alfa)
Aranesp is a recombinant erythropoietic protein (a protein that
stimulates production of red blood cells, which carry oxygen). Amgen
revolutionized the treatment of anemia with the development of
recombinant erythropoietin, Epoetin alfa. Building on this heritage,
Amgen developed Aranesp, a unique erythropoiesis stimulating protein,
which contains two additional sialic acid-containing carbohydrate
chains compared to the Epoetin alfa molecule and remains in the
bloodstream longer than Epoetin alfa because it has a longer
half-life. Aranesp was approved by the U.S. Food and Drug
Administration (FDA) in September 2001 for the treatment of anemia
associated with chronic renal failure, also known as chronic kidney
disease (CKD), for patients on dialysis and patients not on dialysis.
In July 2002, Aranesp was approved by the FDA for the treatment of
chemotherapy-induced anemia in patients with non-myeloid malignancies.
Important Safety Information
Aranesp is indicated for the treatment of anemia in patients with
nonmyeloid malignancies where anemia is due to the effect of
concomitantly administered chemotherapy.
Aranesp is contraindicated in patients with uncontrolled
hypertension. Erythropoietic therapies may increase the risk of
thrombotic events and other serious events. The target hemoglobin (Hb)
should not exceed 12 g/dL. If the Hb increase exceeds 1.0 g/dL in any
2-week period, dose reductions are recommended. In a study with
another erythropoietic product, where the target Hb was 12 - 14 g/dL,
an increased incidence of thrombotic events, disease progression, and
mortality was seen.
Cases of pure red cell aplasia (PRCA) and of severe anemia, with
or without other cytopenias associated with neutralizing antibodies to
erythropoietin have been reported in patients treated with Aranesp.
This has been reported predominately in patients with chronic renal
failure (CRF) receiving Aranesp by subcutaneous administration. A
sudden loss of response to Aranesp, accompanied by severe anemia and
low reticulocyte count, should be evaluated. If anti-erythropoietin
antibody-associated anemia is suspected, Aranesp and other
erythropoietic proteins should be withheld. Aranesp should be
permanently discontinued in patients with antibody-mediated anemia.
Patients should not be switched to other erythropoietic proteins.
The most commonly reported side effects in clinical trials were
fatigue, edema, nausea, vomiting, diarrhea, fever, and dyspnea.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science´s promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a broad and deep pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people´s lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
This news release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed below
and others that can be found in Amgen´s Form 10-K for the year ended
December 31, 2005, and in Amgen´s periodic reports on Form 10-Q and
Form 8-K. Amgen is providing this information as of the date of this
news release and does not undertake any obligation to update any
forward-looking statements contained in this document as a result of
new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results
may differ materially from those we project. Discovery or
identification of new product candidates or development of new
indications for existing products cannot be guaranteed and movement
from concept to product is uncertain; consequently, there can be no
guarantee that any particular product candidate or development of a
new indication for an existing product will be successful and become a
commercial product. Further, preclinical results do not guarantee safe
and effective performance of product candidates in humans. The
complexity of the human body cannot be perfectly, or sometimes, even
adequately modeled by computer or cell culture systems or animal
models. The length of time that it takes for us to complete clinical
trials and obtain regulatory approval for product marketing has in the
past varied and we expect similar variability in the future. We
develop product candidates internally and through licensing
collaborations, partnerships and joint ventures. Product candidates
that are derived from relationships may be subject to disputes between
the parties or may prove to be not as effective or as safe as we may
have believed at the time of entering into such relationship. Also, we
or others could identify side effects or manufacturing problems with
our products after they are on the market. In addition, sales of our
products are affected by the availability of reimbursement and the
reimbursement policies imposed by third party payors, including
governments, private insurance plans and managed care providers, and
may be affected by domestic and international trends toward managed
care and healthcare cost containment as well as possible U.S.
legislation affecting pharmaceutical pricing and reimbursement.
Government regulations and reimbursement policies may affect the
development, usage and pricing of our products. In addition, we
compete with other companies with respect to some of our marketed
products as well as for the discovery and development of new products.
We believe that some of our newer products, product candidates or new
indications for existing products, may face competition when and as
they are approved and marketed. Our products may compete against
products that have lower prices, established reimbursement, superior
performance, are easier to administer, or that are otherwise
competitive with our products. In addition, while we routinely obtain
patents for our products and technology, the protection offered by our
patents and patent applications may be challenged, invalidated or
circumvented by our competitors and there can be no guarantee of our
ability to obtain or maintain patent protection for our products or
product candidates. We cannot guarantee that it will be able to
produce commercially successful products or maintain the commercial
success of our existing products.
Our stock price may be affected by actual or perceived market
opportunity, competitive position, and success or failure of our
products or product candidates. Further, the discovery of significant
problems with a product similar to one of our products that implicate
an entire class of products could have a material adverse effect on
sales of the affected products and on our business and results of
operations. The scientific information discussed in this news release
related to our product candidates is preliminary and investigative.
Such product candidates are not approved by the U.S. Food and Drug
Administration (FDA), and no conclusions can or should be drawn
regarding the safety or effectiveness of the product candidates. Only
the FDA can determine whether the product candidates are safe and
effective for the use(s) being investigated. Further, the scientific
information discussed in this news release relating to new indications
for our products is preliminary and investigative and is not part of
the labeling approved by the FDA for the products. The products are
not approved for the investigational use(s) discussed in this news
release, and no conclusions can or should be drawn regarding the
safety or effectiveness of the products for these uses. Only the FDA
can determine whether the products are safe and effective for these
uses. Healthcare professionals should refer to and rely upon the
FDA-approved labeling for the products, and not the information
discussed in this news release.
EDITOR´S NOTE: An electronic version of this news release may be
accessed via our Web site at www.amgen.com. Journalists and media
representatives may sign up to receive all news releases
electronically at time of announcement by filling out a short form in
the Media section of the Web site.
CONTACT: Amgen, Thousand Oaks
Marie Fay, 805-447-4587 (media)
Arvind Sood, 805-447-1060 (investors)